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The nuclear and oncogenic BCL-3 protein activates or represses gene transcription when bound to NF-B
proteins p50 and p52, yet the molecules that specifically interact with BCL-3 and drive BCL-3-mediated effects
on gene expression remain largely uncharacterized. Moreover, GSK3-mediated phosphorylation of BCL-3
triggers its degradation through the proteasome, but the proteins involved in this degradative pathway are
poorly characterized. Biochemical purification of interacting partners of BCL-3 led to the identification of
CtBP as a molecule required for the ability of BCL-3 to repress gene transcription. CtBP is also required for
the oncogenic potential of BCL-3 and for its ability to inhibit UV-mediated cell apoptosis in keratinocytes. We
also defined the E3 ligase TBLR1 as a protein involved in BCL-3 degradation through a GSK3-independent
pathway. Thus, our data demonstrate that the LSD1/CtBP complex is required for the repressing abilities of
an oncogenic IB protein, and they establish a functional link between the E3 ligase TBLR1 and NF-B.
Numerous oncogenic proteins are aberrantly expressed be-
cause the molecules involved in their degradation are not func-
tioning properly (22, 24, 44). BCL-3 is an IB protein whose
degradation through the proteasome requires GSK3-mediated
phosphorylation, yet the E3 ligase involved in this pathway is
unknown (42). BCL-3 was originally identified through molec-
ular cloning of the breakpoint of the t(14;19) chromosomal
translocation found in a subset of human B-cell chronic lym-
photic leukemias (27). This translocation triggers BCL-3 over-
expression and, consequently, the deregulation of many genes
involved in survival and cell proliferation (30). Aberrant
BCL-3 expression has also been reported in multiple myelomas
and subtypes of lymphomas, even in the absence of any t(14;
19) chromosomal translocation (6, 7, 26, 29). Deregulated
BCL-3 expression has also been seen in breast and nasopha-
ryngeal cancers, hepatocarcinomas, and familial cylindromato-
sis. Familial cylindromatosis is a genetic disease characterized
by benign tumors of hair-follicle keratinocytes due to some
loss-of-function mutations of CYLD, a deubiquitinating en-
zyme that limits the nuclear import of BCL-3 (4, 12, 25, 31, 41).
Insight into the role of BCL-3 in the immune system has
been provided through the analysis of bcl-3-deficient mice.
These mice have defects in the organogenesis of Peyer’s
patches, in germinal-center formation, and in the microarchi-
tecture of the spleen and lymph nodes, and they exhibit select
defects upon immunological challenge (16, 32, 36). A role for
BCL-3 in the central tolerance of the thymus was also revealed
in NF-B2-deficient mice (51). Mice deficient in both bcl-3 and
NF-B2 show a complete block in secondary lymphoid orga-
nogenesis as well as defects in thymic stromal cells, and they
develop lymphocytic infiltrates in multiple organs (51). This
severe phenotype, combined with the overlapping phenotypes
of mice deficient in bcl-3 or p52, support the notion that BCL-3
and p52 have redundant biological effects in vivo (15, 16, 51).
BCL-3 activates gene transcription by removing the inhibi-
tory NF-B p50 and p52 homodimers from DNA and/or by
acting as a coactivator for a subset of NF-B target genes (13,
17, 23). BCL-3 can also negatively regulate lipopolysaccharide
(LPS)-induced tumor necrosis factor alpha (TNF-) synthesis
in macrophages when bound to histone deacetylase 1
(HDAC1) and HDAC3 and/or because BCL-3 prevents the
degradative polyubiquitination of p50 inhibitory homodimers
(8, 21, 46).
To learn more about the regulation of BCL-3, we have
purified BCL-3-associated proteins and have identified CtBP,
LSD1, and TBLR1 as proteins that all bind to the N-terminal
domain of this oncoprotein. CtBP is crucial in the biology of
BCL-3: this corepressor is required for the stabilization of
BCL-3 and for the ability of BCL-3 to repress gene transcrip-
tion, to transform cells, and to inhibit UV-mediated cell
apoptosis in transformed keratinocytes. Moreover, the half-life of
BCL-3 is extended in TBLR1-depleted cells due to altered
polyubiquitination, thus defining TBLR1 as a key molecule for
BCL-3 degradation. Therefore, our data identified the N-ter-
minal domain of BCL-3 as an essential region for the degra-
dation, transcriptional activity, and oncogenic potential of this
protein and defined CtBP and TBLR1 as key regulators of
different properties of the BCL-3 oncoprotein.
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MATERIALS AND METHODS
Cell culture, biological reagents, and treatments. 293, Phoenix, NIH 3T3,
HeLa, and Karpas cells were cultured as described previously (42). HaCat cells
were maintained in Dulbecco’s modified Eagle medium (DMEM) supplemented
with 10% fetal bovine serum (FBS), 1% glutamine, and 1% penicillin-strepto-
mycin.
MG132 and LiCl were purchased from A&E Scientific (Marcq, Belgium) and
Sigma (St. Louis, MO), respectively. Polyclonal antibodies against hemagglutinin
(HA), HDAC3, Hsp90, Myc, BCL-3, IB, IB, and IBε as well as monoclo-
nal antibodies against ubiquitin, CtBP, and Myc were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). Monoclonal anti-FLAG antibodies and beads
were purchased from Sigma. Polyclonal antibodies against LSD1, p52/p100, and
p105/p50 were from Abcam (Cambridge, United Kingdom) and Millipore (Te-
mecula, CA), respectively. The monoclonal anti-TBLR1 antibody was from Ab-
nova (Taipei, Taiwan). GFP, TBLR1, and CtBP small interfering RNAs (siRNAs)
were purchased from Dharmacon (Lafayette, CO), whereas LSD1 siRNAs were
from Eurogentec (Liege, Belgium).
Plasmids, retroviral constructs, and lentiviral constructs. pMT2T p50, pMT2T
BCL-3, pMT2T BCL-3 K13-26R, pMT2T BCL-3 MTS, pMT2T BCL-3 N
(which lacks the first 112 amino acids), and FLAG-BCL-3, -N, -C, and -NC
have been described previously, as has FLAG-IB (5, 42, 43). BCL-3 N10 and
-N30 constructs were generated by PCR, whereas BCL-3 ANK M123, BCL-3
LAV, and BCL-3 5KR mutants were generated by mutagenesis. The HA-BCL-
3-expressing construct was generated by subcloning the corresponding cDNA
into the HA-pcDNA3 vector. The HA-p52-, HA-p100-, and HA-p105-expressing
constructs were gifts from E. Dejardin (University of Liege, Liege, Belgium)
(14). The pBabe BCL-3 and RasV12 constructs have been described previously,
whereas the pBabe BCL-3 LAV mutant was generated by subcloning the corre-
sponding cDNA coding sequence into the pBabe construct. The BCL-3 lentiviral
construct was generated by subcloning the BCL-3 cDNA into the pLL3.7 lenti-
virus construct (a gift from L. van Parijs). FLAG-p52 was generated by PCR
using pMT2T p52 as the template. Myc-TBLR1 was generated by reverse tran-
scription-PCR (RT-PCR) using total RNAs from 293 cells and subsequent clon-
ing into the pCMV-Myc vector (Invitrogen, Carlsbad, CA). The Myc-TBLR1 N
mutant, which lacks the first 100 amino acids, was generated by PCR using
Myc-TBLR1 as the template. Myc-CtBP, FLAG-CtBP, and FLAG-CoREST
were kindly provided by E. Olson (Southwestern Medical Center, University of
Texas, Dallas, TX), J. Mymryk (Department of Oncology, London Regional
Cancer Program, and Department of Biochemistry, University of Western On-
tario, London, Ontario, Canada), and G. Gill (Department of Pathology, Har-
vard Medical School, Boston, MA), respectively. The HDAC3 expression con-
structs have been described previously (43).
Immunoprecipitations and immunofluorescence. Immunoprecipitations in-
volving ectopically expressed and/or endogenous proteins, as well as immuno-
fluorescence, were performed as previously described (35, 42).
Retroviral transduction and formation of foci. Infection of NIH 3T3 cells was
performed according to instructions from G. Nolan’s laboratory (http://www
.stanford.edu/group/nolan/retroviral_systems/retsys.html). For focus assays,
1.5  106 infected NIH 3T3 cells were seeded in a 10-cm-diameter plate, and the
medium was changed every 3 days. The cell cultures were followed for 3 weeks,
and colonies were visualized with Giemsa staining.
Lentiviral infections, Affymetrix microarray analysis, and real-time PCR. In-
fections of HaCat cells using the control or BCL-3 pLL3.7-expressing constructs
were carried out as previously described (35). For Affymetrix microarrays, total
RNAs were extracted from the resulting HaCat cells cultured in triplicate, using
the RNeasy Mini kit from Qiagen (Valencia, CA). The integrity of the RNAs
from those six distinct experimental conditions was checked with the Agilent
Bioanalyzer using the RNA 6000 Nano kit (Agilent, Santa Clara, CA). Biotin
labeling of cRNA, subsequent hybridization on the GeneChip Human Genome
U133A 2.0 (Affymetrix, Santa Clara, CA), and scanning were performed accord-
ing to the manufacturer’s instructions.
For real-time PCRs, total RNAs were extracted using the EZNA Total RNA
kit (Omega Bio-Tek, Norcross, GA), and cDNAs were synthesized using the
RevertAid H Minus First Strand cDNA synthesis kit (Fermentas, Glen Burnie,
MD). Subsequent PCRs were carried out using the Power SYBR green PCR
master kit (Applied Biosystems, Foster City, CA) on the LightCycler 480
(Roche). Primers, whose sequences are available upon request, were designed
using Primer Express software.
ChIP assays. Chromatin immunoprecipitation (ChIP) assays were conducted
as previously described, with minor modifications (11). Briefly, trypsinized cells
were cross-linked with 1% paraformaldehyde, lysed in a sodium dodecyl sulfate
(SDS) lysis buffer, and sonicated using the Bioruptor (Diagenode, Lie`ge, Bel-
gium) (11). Extracts were precleared by 1 h of incubation with protein A-herring
sperm DNA, and immunoprecipitation was performed by overnight incubation at
4°C with the relevant antibody, using an anti-HA antibody as negative control,
followed by 1 h of incubation with protein A-herring sperm DNA. Protein-DNA
complexes were washed as per standard ChIP techniques. After elution, protein-
ase K treatment, and reversal of cross-links, DNA fragments were analyzed by
real-time PCR with a SYBR Green PCR master kit (Applied Biosystems, Foster
City, CA) on the LightCycler 480 (Roche Applied Sciences, Basel, Switzerland).
Input DNA was analyzed simultaneously and used for normalization. For further
normalization, the signal obtained from a region within the glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) gene located 2,500 bp downstream of the
poly(A) site, where RNA polymerase II (Pol II) is known not to be recruited, was
used to compensate for possible fluctuations arising during handling. Primer
sequences for the B site within the PLAUR promoter and for the region within
the GAPDH gene are available upon request.
Caspase 3/7 activation assays. Control, wild-type (WT) BCL-3-, or BCL-3
LAV-expressing HaCat cells were seeded into 24-well plates. The next day, the
cells were either left untreated or subjected to UV irradiation (56 J/m2) for 5, 15,
or 30 min; then they were cultured in DMEM for 24 h. Activation of caspase 3
and caspase 7 (caspase 3/7) was assessed by using the Caspase Glo 3/7 assay kit
(Promega, Madison, WI) according to the protocol provided by the manufac-
turer.
In-gel tryptic digestion and identification by nano-liquid chromatography–
tandem mass spectrometry (nano-LC–MS-MS). In-gel digestion was performed
by addition of modified trypsin (Promega, Madison, WI) in 50 mM ammonium
bicarbonate at 37°C overnight. The tryptic digests were air dried and placed in
formic acid (0.1%) for further MS-MS analysis.
Each in-gel digest of an individual band was analyzed by nano-high-perfor-
mance liquid chromatography (HPLC) electrospray MS-MS using an XCT ion-
trap mass spectrometer (Agilent, Santa Clara, CA). The HPLC separations were
performed on an RP C18 Zorbax column (150 mm by 75 m; particle size, 3.5
m) from Agilent. The mobile phase was a 90-min gradient mixture formed as
follows: mixture A, water-acetonitrile-formic acid (97/3/0.1 [vol/vol/vol]); mixture
B, acetonitrile-water-formic acid (90/10/0.1 [vol/vol/vol]). The flow rate was 300
nl/min. The collision energy was set automatically depending on the mass of the
parent ion. Each MS full scan was followed by MS-MS scans of the first four most
intense peaks detected in the prior MS scan. A list of peptide masses was
subsequently introduced into the database for protein identification searches
using MASCOT (Matrix Sciences).
RESULTS
CtBP and TBLR1 bind BCL-3 through its N-terminal do-
main. To learn more about BCL-3 function, we initiated a
study directed toward identifying its binding partners. There-
fore, we created a 293 cell line stably expressing FLAG-BCL-3.
This cell line was then treated with MG132, and FLAG-BCL-3
was affinity purified. Copurifying proteins were identified by
silver staining and mass spectrometry analysis after separation
of BCL-3 complexes by SDS-polyacrylamide gel electrophore-
sis (PAGE) (Fig. 1A). Proteins coprecipitating with BCL-3
included Hsp70, BAG-2, the corepressors CtBP1 and CtBP2,
and the TBL1-related protein (TBLR1), initially identified as a
component of the nuclear receptor corepressor (N-CoR) com-
plex (Fig. 1A) (48–50). In agreement with previous results,
HDAC3 and p50 also bound BCL-3, as evidenced by Western
blot analysis performed on the anti-FLAG immunoprecipitates
(Fig. 1B). Western blotting with antibodies against CtBP and
TBLR1, carried out on those anti-FLAG immunoprecipitates,
also confirmed that both proteins are BCL-3-associated pro-
teins (Fig. 1B).
FLAG-CtBP bound overexpressed BCL-3 in 293 cells (Fig.
2A, top panel, lane 3). Similarly, FLAG-CtBP was also found
in the anti-BCL-3 immunoprecipitate (Fig. 2A, second panel
from top, lane 3). Importantly, BCL-3 also associated with
CtBP at the endogenous level in Karpas cells (Fig. 2B, top
panel, lane 2). BCL-3 associates with CtBP independently of
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its binding to NF-B proteins, as evidenced by the fact that a
BCL-3 mutant that fails to bind to p50 or p52 because of point
mutations generated within its ankyrin repeats (BCL-3 ANK
M123) still bound CtBP (data not shown). The N-terminal
domain of BCL-3 is required for binding to CtBP, as evidenced
by the fact that a mutant of BCL-3 that lacks the domain
upstream of the ankyrin repeats (BCL-3 N) did not associate
with this corepressor, while another mutant, lacking the C-
terminal domain downstream of the ankyrin repeats (BCL-3
C), still did (Fig. 2C, top panel, lanes 5 and 7, respectively).
Many, if not all, CtBP-interacting proteins harbor a conserved
PXDLS motif required for binding to this corepressor (9).
Because the first 10 N-terminal amino acids of BCL-3 included
a PVDLR sequence from amino acid 5 to 9, we generated a
mutant in which this motif was mutated into a LVAVR se-
quence (BCL-3 LAV) and tested its ability to bind to CtBP.
Disruption of this PVDLR motif impaired the binding of
BCL-3 to CtBP (Fig. 2D, top panel, lane 5). Thus, BCL-3 binds
CtBP through an N-terminal PVDLR sequence. This motif
was dispensable for the binding of BCL-3 to HDAC3, even if
the entire N-terminal domain was required for this interaction
(data not shown). Therefore, BCL-3 binds the corepressors
CtBP and HDAC3 through two distinct domains. Of note,
strong colocalization of BCL-3 and CtBP was observed upon
overexpression of both proteins in HeLa cells (Fig. 2E, top
panel on the right). Such colocalization with CtBP was not
observed with a mutant lacking the first 10 N-terminal amino
acids (BCL-3 N10), which failed to bind to this corepressor
(data not shown). BCL-3 actually recruited CtBP to the nu-
cleus in some dots, as evidenced by the fact that CtBP was not
as intensively localized in the nucleus when transfected alone
(Fig. 2E, bottom panel).
The NF-B protein p52 failed to bind Myc-CtBP (Fig. 3A,
top panel, lane 5). However, p52 bound CtBP in the presence
of overexpressed BCL-3 (Fig. 3B, top panel, lane 7), which
suggests that the latter IB protein mediates the binding of p52
to CtBP. The existence of a ternary complex that includes
BCL-3, p52, and CtBP was demonstrated in 293 cells (Fig. 3B,
top panel, lane 6). We next investigated whether other IB
proteins bind CtBP. Bioinformatic analysis indicated that none
of them harbored a conserved PXDLS motif, and this was
supported by our data showing that overexpressed IB, p100,
and p105 failed to bind FLAG-CtBP (Fig. 3C, top panel, lane
5, and Fig. 3D, top panel, lanes 6 and 8, respectively). A similar
conclusion also applied with endogenous IB, IB, IBε,
p100, and p105, which failed to bind CtBP, whereas LSD1,
used as a positive control, did (Fig. 3E, lane 2). Taken to-
gether, our data suggest that BCL-3 is the only tested IB
family member that binds CtBP.
TBLR1 was also identified as a BCL-3-interacting protein
(Fig. 1A). BCL-3 bound TBLR1 both in transfected 293 cells
and at the endogenous level in Karpas cells (Fig. 4A, top panel,
lane 4, and Fig. 4B, top panel, lane 2, respectively). There
again, the N-terminal domain of BCL-3 was required for this
association, even if the PVDLR motif was dispensable (Fig.
4C, top panel, lanes 7 and 5, respectively). BCL-3 N10, but
not BCL-3 N30 and -N, bound TBLR1 in 293 cells (Fig. 4D,
top panel, compare lanes 3 and 5). TBLR1 harbors an N-
terminal Lis homology (LisH) motif required for oligomeriza-
tion, transcriptional repression, and binding to histones H2B
and H4 (10, 48). This region was dispensable for binding to
BCL-3, as a TBLR1 N mutant lacking the first 100 amino
acids, which include this domain, still bound BCL-3 similarly to
full-length TBLR1 (Fig. 4E, top panel, lanes 5 and 4, respec-
tively).
TBLR1 was dispensable for the binding of CtBP to BCL-3,
as this association was unchanged in TBLR1-depleted BCL-3-
expressing 293 cells (Fig. 4F, top panel, compare lanes 2 and
4). Moreover, TBLR1 was found in the anti-BCL-3 but not in
the anti-CtBP immunoprecipitate (Fig. 4G, top panel, lanes 2
and 4, respectively), suggesting the existence of two distinct
BCL-3 subcomplexes, one with CtBP and the other with
TBLR1. This hypothesis is further supported by the fact that
we did not detect any ternary complex that would have in-
cluded CtBP, BCL-3, and TBLR1 (Fig. 4G, top panel, lane 8).
Thus, our data suggest that BCL-3 can form distinct subcom-
plexes.
A role for CtBP in the repressing abilities of BCL-3 and in
its stability. Although CtBP and TBLR1 were defined as pro-
FIG. 1. Identification of multiple BCL-3-associated proteins
through biochemical purification. (A) (Top) Mock-expressing 293 cells
or 293 cells stably expressing FLAG-BCL-3, treated with MG132 (20
M) for 4 h, were subjected to anti-FLAG immunoprecipitation (lanes
1 and 2, respectively). Immunoprecipitated proteins were subsequently
released from the beads using the FLAG peptide and were subjected
to SDS-PAGE, silver staining, and mass spectrometric analysis for
identification. (Bottom) Western blotting (WB) with an antibody
against BCL-3 was carried out on the immunoprecipitates. (B) (Top)
Western blot analysis of anti-FLAG immunoprecipitates (IP) from
MG132-treated mock-expressing or FLAG-BCL-3-expressing cells
(odd and even lanes, respectively). Western blotting was carried out
with antibodies against p50 and HDAC3 (positive controls) and
against CtBP and TBLR1 (identified by mass spectrometry), as indi-
cated, to validate the identifications obtained by mass spectrometry.
(Bottom) Western blotting was also carried out with antibodies against
p50, HDAC3, CtBP, and TBLR1 by using 5% of the extracts used in
immunoprecipitation experiments.
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FIG. 2. BCL-3 interacts with CtBP through its N-terminal PVDLR motif. (A) (Top two panels) Ectopically expressed CtBP interacts with
BCL-3. 293 cells were transfected with the indicated expression plasmids, and cell extracts were subjected to immunoprecipitation (IP) with an
anti-FLAG or anti-BCL-3 antibody, followed by Western blot analysis (WB) with an anti-BCL-3 or anti-FLAG antibody. (Bottom two panels)
Crude cell extracts were subjected to Western blotting with antibodies against BCL-3 and FLAG, as indicated. (B) (Top) Endogenous CtBP and
BCL-3 are associated in vivo. Extracts from Karpas cells were subjected to immunoprecipitation with an anti-HA (negative control) or anti-BCL-3
antibody, followed by Western blotting with an antibody against CtBP. (Center and bottom) Cell extracts were also subjected to Western blot
analysis with antibodies against CtBP and BCL-3. (C and D) The PVDLR motif located within the first 10 N-terminal amino acid residues of BCL-3
is required for binding to CtBP. (Top) 293 cells were transfected with the indicated expression plasmids, and crude cell extracts were subjected
to anti-FLAG immunoprecipitation, followed by Western blot analysis with an anti-Myc antibody. (Center and bottom) Crude cell extracts were
also subjected to Western blotting with antibodies against FLAG and Myc. The PVDLR motif of BCL-3 is shown, as well as the mutations within
this motif in the BCL-3 LAV mutant. (E) Wild-type BCL-3, but not the BCL-3 N10 mutant, colocalizes with CtBP. Immunofluorescence analysis
with an anti-FLAG or anti-Myc antibody was carried out on HeLa cells cotransfected with a Myc-CtBP expression vector and either wild-type
FLAG-BCL-3 or the BCL-3 N10 mutant. The panel at the bottom shows the localization of CtBP when transfected alone into HeLa cells.
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FIG. 3. BCL-3 is the only IB protein that binds CtBP. (A) BCL-3 but not p52 binds CtBP in transfected cells. (Top) 293 cells were transfected
with the indicated expression plasmids, and anti-FLAG immunoprecipitation (IP), followed by Western blotting (WB) with an anti-CtBP antibody,
was carried out with the cell extracts. (Center and bottom) Western blot analyses with antibodies against FLAG and CtBP were also performed
with the crude cell extracts. (B) Evidence for a ternary complex that includes p52, BCL-3, and CtBP. (Top panel) 293 cells were transfected with
the indicated expression plasmids, and cell lysates were first subjected to anti-FLAG immunoprecipitation. A FLAG peptide was subsequently
added in order to release the immunoprecipitates, which were then immunoprecipitated using the anti-BCL-3 antibody (lanes 1 to 6). The
anti-FLAG immunoprecipitate from lane 7 was used directly for Western blotting with an anti-Myc antibody to detect Myc-CtBP, as were the
anti-BCL-3 immunoprecipitates from lanes 1 to 6. (Center and bottom panels) Crude cell extracts were also subjected to Western blotting as
indicated. (C and D) BCL-3, but not p52, p100, p105, or IB, binds CtBP. (Top) 293 cells were transfected with the indicated expression plasmids.
Immunoprecipitation with an anti-Myc (C) or anti-FLAG (D) antibody was carried out with the cell extracts, followed by Western blotting with
an anti-FLAG (C) or anti-HA (D) antibody (top panels). (Center and bottom) Western blot analyses with antibodies against FLAG (C and D),
Myc (C), and HA (D) were also performed with the crude cell extracts. (E) Ectopically expressed CtBP binds LSD1 but not IB, IB, IBε,
p100, or p105. 293 cells were transfected with FLAG-CtBP or an empty FLAG-expressing construct, as indicated (lanes 4 and 3, respectively), and
anti-FLAG immunoprecipitation was carried out on the cell extracts. Western blotting using the indicated antibodies was subsequently performed
on the immunoprecipitates (lanes 1 and 2) and on the cell extracts (lanes 3 and 4).
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FIG. 4. TBLR1 interacts with BCL-3 through the N-terminal domain but not with CtBP. (A and B) BCL-3 and TBLR1 interact in transfected
293 cells and at the endogenous level. (Top) Cell extracts from 293 (A) or Karpas (B) cells treated with MG132 (20 M) were subjected to
immunoprecipitation (IP) with an anti-HA (B) (negative control) or anti-BCL-3 antibody, followed by Western blot analysis (WB) with an anti-Myc
(A) or anti-TBLR1 (B) antibody. (Center and bottom) Crude cell extracts were subjected to Western blotting with antibodies against TBLR1 (B),
Myc (A), and BCL-3 (A and B) as well. (C and D) BCL-3 associates with TBLR1 through its N-terminal domain. 293 cells were transfected with
the indicated expression plasmids, and cell extracts were subjected to immunoprecipitation and Western blot analysis, as indicated. (E) The
N-terminal LisH domain of TBLR1 is dispensable for binding to BCL-3. (Top) 293 cells were transfected with the indicated expression plasmids,
and cell extracts were subjected to immunoprecipitation with an anti-BCL-3 antibody, followed by Western blotting with an anti-Myc antibody.
(Center and bottom) Cell extracts were also subjected to Western blotting with antibodies against Myc and BCL-3. (F) TBLR1 is dispensable for
the association of BCL-3 with CtBP. (Top panel) 293 cells depleted of GFP (negative control) or TBLR1 were transfected with the indicated
expression plasmids, and cell extracts were subjected to immunoprecipitation with an anti-FLAG antibody, followed by Western blotting with an
anti-Myc antibody. (Center and bottom panels) Cell extracts were subjected to Western blotting with antibodies against Myc, FLAG, and TBLR1
as well. (G) Evidence for distinct CtBP- and TBLR1-containing BCL-3 subcomplexes. (Top panel) 293 cells were transfected with the indicated
expression plasmids, and cell lysates were subjected to immunoprecipitation with an anti-BCL-3 (lanes 1 and 2) or anti-FLAG (lanes 3 to 8)
antibody. The resulting immunoprecipitates were subsequently subjected to Western blotting with an anti-TBLR1 antibody (lanes 1 to 4) or were
released from the beads using a FLAG peptide (lanes 5 to 8). The released materials were subsequently subjected to immunoprecipitation with
an anti-BCL-3 antibody followed by Western blotting with an anti-TBLR1 antibody (lanes 5 to 8). (Center and bottom panels) Crude cell extracts
were subjected to Western blotting with antibodies against TBLR1, BCL-3, and FLAG as well.
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teins associated with BCL-3 through its N-terminal domain, it
was unclear how they modulate the transcriptional ability of
BCL-3 and/or its stability. To assess the potential role of CtBP
in BCL-3 stability, we measured the half-life of BCL-3 in
CtBP-depleted cells. CtBP contributes to the stability of
BCL-3, as the half-life of BCL-3 was slightly decreased upon
CtBP depletion in BCL-3-expressing 293 cells or in Karpas
cells (Fig. 5A, top panels, compare lanes 1 to 5 with lanes 6 to
10). A quantification further supported this observation.
Because CtBP is a corepressor, we next determined whether
CtBP modulates the transcriptional potential of BCL-3. We
performed microarray analyses in HaCat cells infected with a
control lentivirus or a BCL-3-expressing lentivirus in order to
identify the genes whose expression is specifically induced or
repressed by this IB protein. We focused our study on the
candidates repressed by BCL-3 (data not shown). The levels of
several genes, including PLAUR, STAP2, AP1S2, and RAB7L1
(39), were decreased upon BCL-3 overexpression in keratino-
cytes (data not shown). PLAUR encodes the receptor for
urokinase plasminogen activator, whereas RAB7L1 encodes a
small GTP binding protein and is a member of the RAS
oncogene family-like (40). A link between NF-B and STAP2,
another BCL-3 target gene, was previously established, as this
gene encodes a scaffold protein that negatively regulates both
canonical and alternative NF-B-activating pathways by Ep-
stein-Barr virus (EBV)-derived latent membrane protein 1
(LMP1) (19). To address the role of CtBP in the capacity of
BCL-3 to repress the expression of these genes, we expressed
either a control lentivirus, WT BCL-3, or the BCL-3 LAV
mutant in HaCat cells. The two BCL-3 products were ex-
pressed at similar levels (Fig. 5B, top panel, compare lanes 2
and 3). We subsequently assessed PLAUR, RAB7L1, STAP2,
and AP1S2 mRNA levels. CtBP was required for the repress-
ing abilities of BCL-3, as the BCL-3 LAV mutant did not
efficiently repress the expression of all these genes (Fig. 5B).
Of note, however, other CtBP-independent mechanisms may
account for the repressing potential of BCL-3, as some candi-
dates, such as PLAUR and AP1S2, were still partially repressed
in cells expressing BCL-3 LAV, which does not bind to CtBP
(Fig. 5B, panels on the left). Therefore, our data suggest that
CtBP is a protein required for the repressing abilities of
BCL-3. ChIP assay analysis also indicated that BCL-3, BCL-3
LAV, and CtBP were recruited to a B site (GGGATCCCCT)
that we identified within the promoter of PLAUR in vivo (Fig.
5C; also data not shown). The recruitment of CtBP to this B
site was impaired in HaCat cells that overexpressed BCL-3
LAV (Fig. 5C, right). Thus, BCL-3 is required to recruit CtBP
on the promoter sequence of PLAUR in vivo, and this mech-
anism may explain why the BCL-3 LAV mutant, whose recruit-
ment to the PLAUR promoter is very similar to that of WT
BCL-3, failed to efficiently repress this gene in keratinocytes.
CoREST and LSD1 are BCL-3-associated proteins. CtBP is
part of a corepressor complex that includes about 50 pro-
teins, such as LSD1, a lysine-specific histone demethylase,
and Co-RE1 silencing transcription factor (CoREST) (2, 37, 38).
Thus, we next explored whether CoREST and LSD1 also bound
BCL-3 by coimmunoprecipitation studies. Ectopically ex-
pressed BCL-3 indeed bound CoREST as well as endogenous
LSD1 in 293 cells (Fig. 6A and B, top panels, lanes 2). The
PVDLR motif within the first 10 N-terminal amino acids of
BCL-3 was required for binding to LSD1 but not to CoREST,
as the BCL-3 LAV mutant failed to bind to LSD1 but still
interacted with CoREST (Fig. 6B, top panel, lane 3, and Fig.
6A, top panel, lane 4, respectively). Of note, BCL-3 ANK
M123 failed to bind LSD1, which indicates that p50 or p52 is
required for the association of BCL-3 with LSD1 (Fig. 6B, top
panel, lane 9). Importantly, CtBP appears to be required for
the binding of BCL-3 to LSD1, as this association was severely
compromised in CtBP-depleted 293 cells, while the binding of
BCL-3 to p50 remained unchanged upon CtBP depletion (Fig.
6C, top panel and second panel from the top, compare lanes 3
and 4 as well as lanes 5 and 6, respectively).
To further explore the roles of both CtBP and LSD1 in the
repressing abilities of BCL-3, we next depleted either CtBP or
LSD1 in control or BCL-3-expressing HaCat cells and assessed
the expression of several target genes through real-time PCR.
Efficient CtBP or LSD1 depletion was achieved through RNA
interference (RNAi) (Fig. 6D, bottom panels, compare lanes 3
and 4 with lanes 1 and 2). Those experiments first confirmed that
both PLAUR expression and RAB7L1 expression were indeed
repressed upon BCL-3 expression in HaCat cells. Moreover,
CtBP depletion efficiently restored the expression of both
PLAUR and RAB7L1 in BCL-3-expressing cells, thus confirm-
ing the requirement of this corepressor for the ability of BCL-3
to repress gene transcription (Fig. 6D). The results obtained
upon LSD1 depletion also suggested a role for this lysine-
FIG. 5. CtBP is required for the repressing abilities of BCL-3 and to prevent excessive BCL-3 degradation. (A) CtBP is required for BCL-3
stability. (Top) GFP (negative control)- or CtBP-depleted, BCL-3-expressing 293 (left) or Karpas (right) cells were either left untreated (lanes 1
and 6) or stimulated with cycloheximide (CHX) (50 g/ml) (lanes 2 to 5 and 7 to 10), and cell extracts were subjected to Western blotting (WB)
with antibodies against Hsp90, BCL-3, and CtBP, as indicated. (Bottom) Quantification of BCL-3 levels under control conditions or upon CtBP
depletion in BCL-3-expressing 293 cells (left) or in Karpas cells (right). The signal intensity in unstimulated GFP siRNA cells is set to 100%.
(B) The N-terminal PVDLR motif is required for the repressing abilities of BCL-3. HaCat cells were infected either with a control lentivirus
(negative control) or with a lentivirus expressing WT BCL-3 or BCL-3 LAV. Western blots with antibodies against BCL-3 and Hsp90, performed
on extracts from the corresponding experimental conditions in order to ensure comparable levels of WT and mutated BCL-3 products, are shown
at the top. Total RNAs from the resulting cells were subjected to real-time PCR in order to assess the mRNA levels of PLAUR, RAB7L1, STAP2,
and AP1S2, all genes repressed by WT BCL-3 in transformed keratinocytes (data not shown). The abundance of transcripts in cells infected with
the control lentivirus was set to 1, and their levels in cells infected with the other lentivirus were relative to that after normalization with 18S rRNA.
Data from three (PLAUR and RAB7L1), four (AP1S2), or five (STAP2) independent experiments (means  standard deviations) are shown.
(C) Chromatin immunoprecipitation assays with an anti-HA (negative control), anti-BCL-3 (left), or anti-CtBP (right) antibody (Ab) were
performed using control, WT BCL-3-expressing, or BCL-3 LAV-expressing HaCat cells. Associated DNA was analyzed by real-time PCR using
primers derived from the promoter of the PLAUR gene (data not shown). Data from two independent experiments (means  standard deviations)
are shown.
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FIG. 6. CoREST and LSD1 bind BCL-3 through its N-terminal domain. CtBP and LSD1 play roles in the repressing abilities of BCL-3. (A and
B) The PVDLR motif of BCL-3 is required for binding to LSD1 but not to CoREST. (Top) Anti-BCL-3 (A) or anti-FLAG (B) immunoprecipitates
(IP) with cell extracts derived from 293 cells transfected with the indicated expression plasmids were subjected to Western blot analysis (WB) with
an anti-FLAG (A) or anti-LSD1 (B) antibody. (Center and bottom) Crude cell extracts were subjected to Western blotting with antibodies against
BCL-3, LSD1, and FLAG, as indicated. (C) The association of BCL-3 with LSD1 is impaired in CtBP-depleted cells. (Top two panels) 293 cells
were first transfected with the indicated siRNA targeting either GFP (negative control) or CtBP, as indicated. The resulting cells were transfected
with the indicated expression vectors, and cell extracts were subjected to immunoprecipitation with an anti-FLAG antibody, followed by Western
blot analysis with an anti-LSD1 or anti-p50 antibody. (Bottom three panels) Crude cell extracts were subjected to Western blotting with an antibody
against LSD1, p50, CtBP, or FLAG, as indicated. (D) CtBP and LSD1 contribute to the repressing abilities of BCL-3. (Top) Control or
BCL-3-expressing HaCat cells were transfected with a siRNA targeting GFP (control) (lanes 1 and 2) or with a siRNA targeting CtBP (left) or
LSD1 (right) (lanes 3 and 4), and cell extracts were subjected to Western blotting with an antibody against Hsp90, BCL-3, CtBP, or LSD1.
(Bottom) Total mRNA levels of PLAUR and RAB7L1 were quantified by real-time PCR under all experimental conditions (control or
BCL-3-expressing cells, as indicated). The abundance of each transcript in cells infected with the control lentivirus was set to 1, and their levels
under the other experimental conditions were relative to that after normalization with 18S rRNA. Data from three independent experiments
(means  standard deviations) are shown.
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specific histone demethylase in the repressing abilities of
BCL-3, although this role may be more promoter specific,
compared to a more general role for CtBP. Indeed, whereas
LSD1 depletion almost totally restored levels of RAB7L1 in
BCL-3-expressing HaCat cells, levels of PLAUR barely
changed upon LSD1 depletion in BCL-3 expressing cells (Fig.
6D). Taken together, our data defined a corepressor, CtBP, and
a lysine-specific histone demethylase, LSD1, as proteins involved
in the repressing abilities of the oncogenic protein BCL-3.
TBLR1 is involved in BCL-3 degradation through a GSK3-
independent pathway. Because TBLR1 acts as an E3 ligase
(33), we next explored whether it was involved in BCL-3 deg-
radation and noticed that the half-life of BCL-3 was increased
in TBLR1-depleted Karpas cells (Fig. 7A, top panel, compare
lanes 1 to 5 with lanes 6 to 10). A quantification further con-
firmed this observation (Fig. 7A, panel at the bottom). To
strengthen the notion that TBLR1 is involved in BCL-3 poly-
ubiquitination, we depleted TBLR1 in MG132-treated Karpas
cells and looked at polyubiquitinated adducts of BCL-3.
TBLR1 depletion impaired endogenous BCL-3 polyubiquitin-
ation (Fig. 7B, top panel, compare lanes 2 and 4). Of note,
some residual polyubiquitinated adducts of BCL-3 were still
detected upon TBLR1 depletion in Karpas cells, indicating
that some TBLR1-independent pathways may also be required
for BCL-3 polyubiquitination.
Since lysines 13 and 26 are the residues subjected to the
polyubiquitination of BCL-3 (42), we explored whether they
were required for the binding of BCL-3 to TBLR1. Whereas
WT BCL-3 bound to Myc-TBLR1 in 293 cells, both BCL-3
K13-26R and BCL-3 5KR, where lysine residues were replaced
with arginines, did not (Fig. 8A, top panel, lanes 2, 4, and 5,
respectively), suggesting that the N-terminal lysine residues are
essential for the binding of BCL-3 to TBLR1. The BCL-3 MTS
mutant still bound TBLR1, suggesting that this E3 ligase mod-
ulates BCL-3 stability through a GSK3-independent pathway
(Fig. 8A, top panel, lane 3). Of note, point mutations within
the ankyrin repeats did not prevent the binding of BCL-3 to
TBLR1 (Fig. 8A, top panel, lane 7). The notion that TBLR1
targets BCL-3 through a GSK3-independent pathway was fur-
ther supported by the fact that treatment with LiCl, a GSK3
inhibitor, had no effect on the binding of BCL-3 to TBLR1 in
MG132-treated 293 cells transfected with TBLR1 and BCL-3
expression constructs (Fig. 8B, top panel, compare lanes 2 and
4). Importantly, TBLR1 has to bind to BCL-3 in order to
destabilize it. Indeed, both the BCL-3 N and 5KR mutants,
which do not associate with this E3 ligase (Fig. 8A), were not
stabilized in TBLR1 RNAi cells, while the level of WT BCL-3
was increased upon TBLR1 depletion (Fig. 8C, top panel,
compare odd with even lanes). Thus, our data suggest that
TBLR1 regulates BCL-3 levels by binding to this IB protein
and by promoting its polyubiquitination through a GSK3-in-
dependent pathway.
To learn more about the role of TBLR1 in the regulation of
the transcriptional potential of BCL-3, we assessed the conse-
quences of TBLR1 depletion for the levels of several genes
repressed by BCL-3 in HaCat cells, namely, PLAUR, RAB7L1,
and STAP2. TBLR1 depletion efficiently restored the expres-
sion levels of these genes in BCL-3-expressing cells, suggesting
that the polyubiquitination of BCL-3 by TBLR1 is required for
its repressing abilities (Fig. 9A). Such a hypothesis was further
FIG. 7. TBLR1 is required for the polyubiquitination of BCL-3.
(A) Extended BCL-3 half-life in TBLR1-depleted cells. (Top) TBLR1-
depleted Karpas cells were either left untreated (lanes 1 and 6) or
stimulated with cycloheximide (CHX) (50 g/ml) (lanes 2 to 5 and 7 to
10), and cell extracts were subjected to Western blotting (WB) with an
antibody against Hsp90, BCL-3, or TBLR1, as indicated. (Bottom)
Quantification of BCL-3 levels under control conditions or upon
TBLR1 depletion in Karpas cells. The signal intensity in GFP siRNA-
treated Karpas cells was set to 100%. (B) Impaired polyubiquitination
(poly-Ub) of BCL-3 upon TBLR1 depletion. Karpas cells transfected
with a siRNA against GFP or TBLR1 were stimulated with MG132.
(Top two panels) Cell extracts were subjected to immunoprecipitation
(IP) with an anti-FLAG (negative control) or anti-BCL-3 antibody,
followed by Western blotting with an antibody against ubiquitin (Ub)
or BCL-3. (Bottom three panels) Cell extracts were subjected to West-
ern blotting with an antibody against BCL-3, Ub, or TBLR1 as well
(bottom panels).
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supported by the fact that the BCL-3 K13-26R mutant, which
failed to be polyubiquitinated, did not repress PLAUR or
RAB7L1 expression any more (Fig. 9B). Taken together, our
data indicate that TBLR1 not only is required for BCL-3
polyubiquitination but also regulates the repressing abilities of
this oncogenic protein.
CtBP is required for the oncogenic potential of BCL-3. Al-
though our results defined CtBP as a candidate required for
the repressing abilities of BCL-3 and for its stability, it was not
clear whether this corepressor had any role in the oncogenic
potential of BCL-3. We addressed this issue by assessing the
ability of WT BCL-3 or the BCL-3 LAV mutant to form col-
onies when expressed in NIH 3T3 cells through retroviral
transductions. The two BCL-3 products were expressed at sim-
ilar levels in these cells (Fig. 10A, top panel, lanes 2 and 3). In
agreement with previous results (42), BCL-3 formed colonies
when expressed in NIH 3T3 cells, but not as strongly as
RasV12, used as a positive control (Fig. 10A). Interestingly,
colony formation was impaired in NIH 3T3 cells that expressed
the LAV mutant, indicating that the binding of BCL-3 to CtBP
is required for its oncogenic potential in vitro (Fig. 10A).
BCL-3 actually promotes cell proliferation through cyclin D1
induction in keratinocytes and also inhibits cell apoptosis by
inducing the expression of HDM2, which acts as an E3 ligase
of p53 (20, 25). Therefore, we explored whether the ability of
BCL-3 to prevent apoptosis in HaCat cells required CtBP. To
address this issue, control, WT BCL-3-expressing, or BCL-3
LAV-expressing cells were either left unstimulated or sub-
jected to UV treatment, and caspase 3/7 activation was subse-
quently assessed. As expected, BCL-3 expression in HaCat
cells inhibited cell apoptosis by preventing caspase 3/7 activa-
tion (Fig. 10B). Interestingly, the BCL-3 LAV mutant failed to
efficiently inhibit caspase 3/7 upon UV treatment, indicating
that the binding of BCL-3 to CtBP is required for its ability to
FIG. 8. BCL-3 requires its N-terminal lysine residues for binding to TBLR1, an E3 ligase acting through a GSK3-independent pathway. (A) The
N-terminal domain of BCL-3, which includes lysines 13 and 26, is required for binding to TBLR1. (Top) 293 cells were transfected with the indicated
expression plasmids, and immunoprecipitation (IP) with an anti-BCL-3 antibody was carried out on the cell extracts, followed by Western blotting (WB)
with an anti-TBLR1 antibody. (Center and bottom) Western blotting with an antibody against TBLR1 or BCL-3 was performed on the crude cell extracts
as well. (B) GSK3 inhibition through LiCl treatment does not affect the binding of BCL-3 to TBLR1. 293 cells were transfected with the indicated
expression plasmids and were subsequently treated with MG132. (Top) Cell extracts were subjected to immunoprecipitation with an anti-BCL-3 antibody,
followed by Western blotting with an anti-TBLR1 antibody. (Center and bottom) Cell extracts were also subjected to Western blotting with an antibody
against TBLR1 or BCL-3. (C) WT BCL-3, but not the N or 5KR mutant, is stabilized in TBLR1-depleted cells. 293 cells were transfected with a siRNA
targeting TBLR1 or GFP (negative control) as indicated. Cells were subsequently transfected with the indicated expression plasmids, and Western
blotting with an antibody against BCL-3, Hsp90, or TBLR1 was performed on the cell extracts.
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prevent cell apoptosis (Fig. 10B). Taken together, our data
defined CtBP as a key molecule that mediates the oncogenic
potential of BCL-3.
DISCUSSION
We report the identification of multiple BCL-3-associated
proteins that are critical for the degradation of BCL-3, for its
ability to repress the expression of several genes in keratino-
cytes, and for its oncogenic potential. Those interactions re-
quire the N-terminal domain of BCL-3, which therefore acts as
a key element for the regulation of BCL-3 activity. We iden-
tified a PVDLR motif within the first 10 N-terminal amino
acids of BCL-3 that is required for binding to the corepressor
CtBP. Mutation of this motif has dramatic consequences for
BCL-3 functions: it abolishes the ability of BCL-3 to repress
the expression of several genes in keratinocytes and also se-
verely impairs the oncogenic potential of BCL-3, at least by
FIG. 9. TBLR1 contributes to the repressing abilities of BCL-3. (A) The repressing abilities of BCL-3 on the expression of PLAUR, RAB7L1, and
STAP2 are abolished in TBLR1-depleted cells. (Top) Control or BCL-3-expressing HaCat cells were transfected with a siRNA targeting GFP (control)
or TBLR1, as indicated, and cell extracts were subjected to Western blotting (WB) with an antibody against BCL-3, TBLR1, or Hsp90, as indicated.
(Bottom) Total RNAs from the resulting cells were subjected to real-time PCR to assess the mRNA levels of PLAUR, RAB7L1, and STAP2. The
abundance of each transcript in control cells infected with the control lentivirus was set to 1, and their levels under the other experimental conditions were
relative to that after normalization with 18S rRNA. Data from three independent experiments (means  standard deviations) are shown. (B) Lysines 13
and 26 of BCL-3 are required for its repressing potential. (Top) Western blotting with antibodies against Hsp90 and BCL-3 was performed on extracts
from HaCat cells expressing either the control lentivirus, WT BCL-3, or the BCL-3 K13-26R mutant, as indicated. (Bottom) PLAUR and RAB7L1
mRNA levels were assessed by real-time PCR. Data from five independent experiments (means  standard deviations) are shown.
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interfering with its capacity to prevent UV-mediated cell
apoptosis. Because this motif is absent in the other NF-B/IB
proteins that we tested, it is not surprising to see that those
candidates failed to bind to CtBP. Thus, CtBP can be defined
as a corepressor that specifically modulates the activity of a
single IB protein rather than as a candidate that universally
regulates NF-B activation through binding to various mem-
bers of this family. We demonstrated that CtBP is a key factor
for the recruitment of additional BCL-3-interacting proteins,
such as LSD1. Still, the recruitment of all BCL-3-interacting
proteins via the N-terminal domain of BCL-3 does not exclu-
sively rely on CtBP; other transcriptional corepressors, such as
HDAC3, bind to BCL-3 through an N-terminal region distinct
from the PVDLR motif. This observation may explain why the
FIG. 10. CtBP is required for the transforming potential of BCL-3 and also for its ability to inhibit caspase 3/7 activation in UV-treated
transformed keratinocytes. (A) (Top) Extracts from NIH 3T3 cells infected with a control pBabe retrovirus or a with a pBabe construct expressing
WT BCL-3 or BCL-3 LAV were subjected to Western blotting (WB) with antibodies against BCL-3 and Hsp90, as indicated. (Center and bottom)
Focus formation assays with NIH 3T3 cells infected with the control vector, the BCL-3 vector, the LAV mutant, or RasV12, used as a positive
control. Focus formation was visualized after coloration with Giemsa stain. Foci were quantified using ImageJ software, in a binary mode (black
and white), from 4 dishes per experimental condition (two distinct infections performed in duplicate for each experimental condition). The
histogram shows the number of foci per dish (means  standard deviations). (B) Inhibition of UV-mediated cell apoptosis by BCL-3 relies on its
interaction with CtBP. Control, WT BCL-3-expressing, or BCL-3 LAV-expressing HaCat cells were either left unstimulated or treated with UV
radiation for the indicated times, and caspase 3/7 activities were quantified and plotted. Caspase 3/7 activities in unstimulated cells infected with
the control lentivirus were set to 1, and their levels under the other experimental conditions were relative to that after normalization of caspase
activities with protein concentrations. Data from three independent experiments (means  standard deviations) are shown.
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repressing abilities of BCL-3 do not rely exclusively on CtBP
and LSD1. Indeed, the BCL-3 LAV mutant still harbors some
residual repressing abilities when recruited to PLAUR or
AP1S2 promoters, for example (Fig. 5B). Therefore, the re-
pressing abilities of BCL-3 actually involve the recruitment of
histone deacetylases, such as HDAC3, as well as CtBP-associ-
ated K9-histone H3 methylase and LSD1 demethylase activi-
ties (38), through distinct subregions within the N-terminal
domain of BCL-3.
Our data also indicate that CtBP protects BCL-3 from ex-
cessive degradation. This may be due to the ability of CtBP to
constitutively bind BCL-3, similarly to NF-B proteins p50 and
p52, which also stabilize BCL-3 through constitutive interac-
tions with the ankyrin repeats of this oncogenic protein.
BCL-3 acts as an oncogenic protein through multiple mech-
anisms that include the induction of cyclin D1 expression in
keratinocytes and also the limiting of cell apoptosis through
induction of the E3 ligase of p53, HDM2 (20, 25). In support
of the latter mechanism, we show here that BCL-3 limits cell
apoptosis in UV-stimulated keratinocytes. Interestingly, this
pathway relies critically on CtBP, as a BCL-3 mutant lacking
the CtBP-interacting motif did not efficiently prevent UV-me-
diated apoptosis in HaCat cells. Our data are in agreement
with previous studies defining CtBP as a protein that promotes
cell survival and tumorigenesis by suppressing the expression
of proapoptotic candidates, many of which are p53-dependent
genes (3, 18). Our results therefore indicate that the oncogenic
potential of BCL-3 also results from its ability to repress gene
transcription, although the identities of BCL-3 target genes
that specifically mediate this function remain to be extensively
characterized. Among them is STAP2, which encodes a scaffold
protein that limits EBV-mediated NF-B activation through
both the canonical and the alternative pathways (19). There-
fore, this finding indicates that the oncogenic protein BCL-3
positively regulates both canonical and alternative NF-B-ac-
tivating pathways by repressing the expression of an inhibitory
protein, namely, STAP2.
The mechanisms underlying BCL-3 degradation remain
poorly characterized. We previously identified a GSK3-depen-
dent degradative pathway that involves the phosphorylation of
two C-terminal residues. We hypothesized that constitutive
Akt activity, seen in many hematological malignancies, may
ultimately contribute to the increased stability of BCL-3
through GSK3 inhibition (42). Elevated levels of BCL-3 in the
nucleus can also be the result of loss-of-function mutations
targeting CYLD (25). Similarly, human papillomavirus (HPV)-
positive cancers, such as cervical and head and neck malignan-
cies, also have elevated levels of nuclear BCL-3, because the
HPV-encoded E6 protein inactivates CYLD under hypoxic
conditions (1). It is also tempting to speculate that loss-of-
function mutations in E3 ligases that target BCL-3 would cause
accumulation of this protein. These results may thus extend the
pathological contexts that lead to elevated expression of BCL-3
in cancer.
Many proteins whose GSK3-dependent phosphorylation
triggers their subsequent degradation bind to the E3 ligase
FBW7 for their K48-linked polyubiquitination. FBW7 sub-
strates, such as c-Myc, c-Jun, Notch1, cyclin D1, and cyclin E,
share a so-called Cdc4 phospho-degron (CPD) (28, 45) that we
actually found on BCL-3 (A. Keutgens et al., unpublished
results). Yet FBW7 does not strongly bind phosphorylated
BCL-3, and the half-life of BCL-3 is not enhanced in FBW7-
depleted cells (Keutgens et al., unpublished). Thus, the E3
ligase that polyubiquitinates BCL-3 upon phosphorylation by
GSK3 remains unknown. Nevertheless, we show here that the
E3 ligase TBLR1 is a BCL-3-associated protein and regulates
BCL-3 stability by promoting its polyubiquitination in a GSK3-
independent pathway. Interestingly, TBLR1 was previously de-
scribed as an exchange factor that mediates “derepression” by
promoting the polyubiquitination and degradation of the N-
CoR/SMRT corepressor complex (33, 34). As a result, and
even if this protein was initially described as a component of
the N-CoR corepressor complex (48–50), TBLR1 promotes
transcriptional activation by mediating the recruitment of the
ubiquitin-proteasome complex to specific target genes (33). In
support of this conclusion, the activation of all NF-B target
genes upon TNF- stimulation is abolished in TBLR1-defi-
cient cells (33). Therefore, TBLR1 positively regulates the
activation of the TNF-- and NF-B-dependent genes.
Our data establish an intimate connection between the
polyubiquitination of BCL-3 and the regulation of its transcrip-
tion potential. Indeed, we show that the ability of BCL-3 to
repress PLAUR, RAB7L1, and STAP2 expression in HaCat
cells is abolished upon TBLR1 depletion. We also show that
the BCL-3 mutant that failed to be polyubiquitinated and to
interact with TBLR1 also failed to repress gene transcription.
Therefore, our data suggest that polyubiquitinated BCL-3 may
actually repress gene transcription just before being degraded.
This concept is in agreement with a previous study which
demonstrated that the polyubiquitination of the coactivator
SRC-3 confers a transcription activation function prior to pro-
moting its degradation (47).
We show here that TBLR1 is required for BCL-3 degrada-
tion through a GSK3-independent pathway, which means that
more than one pathway triggers BCL-3 degradation, as re-
ported for other oncogenic proteins. Interestingly, the contri-
bution of the two degradative pathways to the oncogenic po-
tential of BCL-3 appears to be distinct. Indeed, while a BCL-3
mutant that fails to be degraded because of point mutations of
its GSK3 phosphorylated sites turned out to be more onco-
genic in vitro and in xenograft studies, another BCL-3 mutant
that does not bind TBLR1 (i.e., the K13-26R mutant) formed
as many colonies as WT BCL-3 in soft agar, even if these
colonies were slightly bigger (42). Why and how two distinct
degradative pathways can differentially regulate the oncogenic
potential of BCL-3 remains an open issue that certainly de-
serves further investigation. Knowing how critical the level of
BCL-3 is for the regulation of its oncogenic potential, resolu-
tion of these issues would be essential for better understanding
of the biology of BCL-3. Moreover, beside TBLR1, other E3
ligases may physically interact with BCL-3 in order to trigger
its degradative polyubiquitination. Future studies will be ded-
icated to the extensive characterization of the E3 ligases that
promote BCL-3 polyubiquitination.
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